June 27, 2017

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins

Read More
June 14, 2017

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

Read More
June 12, 2017

Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer

Read More
May 30, 2017

Merck KGaA, Darmstadt, Germany Licenses Selexis SUREtechnology Platform for Immuno-Oncology Antibody Program

Read More
May 23, 2017

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Read More